Health status and costs of exacerbations of chronic bronchitis and COPD: how to improve antibiotic treatment.

abstract：:In this article, we will focus on how preferences and utilities are measured, including the strengths and limitations of various approaches, discuss their use in estimating quality-adjusted life-years (QALYs) and make some recommendations for further research. Preferences are either measured using direct (visual analo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Revicki DA,Lenderking WR

更新日期：2012-02-01 00:00:00

abstract：:This article systematically appraises the findings and conclusions derived from six recent studies of the economic impact and relative value of using percutaneous ventricular assist devices to render short-term hemodynamic support to high-risk patients with particular attention to the settings of cardiogenic shock and...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Maini B,Scotti DJ,Gregory D

更新日期：2014-06-01 00:00:00

abstract：:By 2018, Medicare payments will be tied to quality of care. The Centers for Medicare and Medicaid Services currently use quality-based metric for some reimbursements through their different programs. Existing and future quality metrics will rely on risk adjustment to avoid unfairly punishing those who see the sickest,...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Al Kazzi ES,Hutfless S

更新日期：2015-01-01 00:00:00

abstract：AIM:To review and compare methods for indirect comparison of aflibercept and ranibizumab in patients with diabetic macular edema. METHODS:Post-stratification, inverse probability weighting based on simulated data, weight optimization, and regression model techniques were used to compare pooled individual patient-level...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Regnier SA,Alsop J,Wright J,Nixon R,Staines H,Fajnkuchen F

更新日期：2016-12-01 00:00:00

abstract：INTRODUCTION:In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kwon SH,Park SK,Byun JH,Lee EK

更新日期：2017-08-01 00:00:00

abstract：:We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Neumann PJ,Saret CJ

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:Chronic pancreatitis (CP) is a leading cause of hospitalization among gastrointestinal diseases resulting in considerable financial burden to patients. However the direct costs for nonsurgical management in CP remains unexplored. METHODS:A cross sectional study was carried out (2011-14) in the Department of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kamat N,Pai G,Mallayasamy SR,Kamath A,S R

更新日期：2018-06-01 00:00:00

abstract：:Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Breau LM

更新日期：2003-06-01 00:00:00

abstract：OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

更新日期：2018-06-01 00:00:00

abstract：:The second Medicines Utilization Research in Africa (MURIA) group workshop and symposium again brought researchers together from across Africa to improve their knowledge of drug utilization (DU) methodologies and exchange ideas to further progress DU research in Africa. This built on extensive activities from the firs...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Massele A,Burger J,Kalemeera F,Jande M,Didimalang T,Kalungia AC,Matshotyana K,Law M,Malone B,Ogunleye O,Oluka M,Paramadhas BD,Rwegerera G,Zinyowera S,Godman B

更新日期：2017-04-01 00:00:00

abstract：:This review considers some of the broad principles that concern quality of life assessment. These are discussed in relation to health-related quality of life (HRQOL) and the measurement of subjective well-being. It is argued that there are serious logical and methodological issues concerning HRQOL measurement, to the ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cummins RA,Lau AL,Stokes M

更新日期：2004-08-01 00:00:00

abstract：:This paper reviews the clinical and pharmacoeconomic studies that have been conducted within Europe for patients undergoing elective hip-replacement surgery. Additionally, we offer a perspective on the possible future clinical use of new agents in orthopedic surgery, such as dabigatran and BAY 59-7939 (rivaroxban). Lo...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Ivanovic N,Beinema M,Brouwers JR,Naunton M,Postma MJ

更新日期：2007-02-01 00:00:00

abstract：INTRODUCTION:There is a lack of knowledge about methods for valuing health intervention-related costs and monetary benefits in the education and criminal justice sectors, also known as 'inter-sectoral costs and benefits' (ICBs). The objective of this study was to develop methods for obtaining unit prices for the valuat...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Drost RM,Paulus AT,Ruwaard D,Evers SM

更新日期：2017-02-01 00:00:00

abstract：:Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

更新日期：2010-06-01 00:00:00

abstract：:Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical tr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wade WE,Spruill WJ

更新日期：2007-06-01 00:00:00

abstract：INTRODUCTION:This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wijnen B,Van Mastrigt G,Redekop WK,Majoie H,De Kinderen R,Evers S

更新日期：2016-12-01 00:00:00

abstract：:The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Zhou XH,Ramsey S

更新日期：2003-10-01 00:00:00

abstract：:A review was undertaken to identify relevant and appropriate heath-utility estimates for patients with atrial fibrillation who had stroke and to appraise them against the published requirements for several countries' Health Technology Assessment agencies: Australia (Pharmaceutical Benefits Advisory Committee), Canada ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lloyd A,Wild D,Gallop K,Cowell W

更新日期：2009-12-01 00:00:00

abstract：:Cutaneous melanoma (CM) is a highly curable skin cancer of melanocytes if diagnosed early. Unfortunately, its invasion into the deeper dermis increases the risk of it spreading to the lymph nodes and distant organs. Spread of metastatic melanoma (MM) to other organs is among one of the most dangerous conditions that i...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hegde UP,Chakraborty N,Mukherji B,Grant Kels JM

更新日期：2011-04-01 00:00:00

abstract：:Electronic medical records (EMRs) have become a common source of data for outcomes research. This review discusses trends in EMR data use for outcomes research as well as strengths and limitations, and likely future developments to help optimize value and use of EMR data for outcomes research. EMR-based studies report...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lin J,Jiao T,Biskupiak JE,McAdam-Marx C

更新日期：2013-04-01 00:00:00

abstract：:Nursing homes are facing increased environmental pressures to improve quality of care. However, this increased emphasis on quality comes at a time when nursing homes are facing revenue constraints as a result of the repeal of the Boren amendment, increased reimbursement based on prospective payment systems and widespr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Weech-Maldonado R,Mor V,Oluwole A

更新日期：2004-02-01 00:00:00

abstract：:The prevalence of multiple chronic conditions (MCC) is increasing among individuals of all ages. MCC are associated with poor health outcomes. The presence of MCC has profound healthcare utilization and cost implications for public and private insurance payers, individuals, and families. Investigators have used a vari...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Sambamoorthi U,Tan X,Deb A

更新日期：2015-01-01 00:00:00

abstract：:The goal of asthma management during pregnancy is to keep the mother symptom free and to prevent complications in the fetus. Asthma is a common chronic condition in pregnancy that, if inadequately treated, has the potential to cause adverse effects for both mother and fetus. Aggressive treatment during pregnancy can d...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Streck MR,Blaiss MS

更新日期：2006-02-01 00:00:00

abstract：:In 2001, the US National Cancer Institute created the Cancer Outcomes Measurement Working Group (COMWG) to assess the state-of-the-science of outcomes assessment in cancer and to make recommendations for moving the field forward. The COMWG focused on methods for assessing patient-reported outcomes (health-related QoL,...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Snyder C,Gotay CC,Lipscomb J

更新日期：2006-08-01 00:00:00

abstract：BACKGROUND:In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-incom...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Vogler S,Zimmermann N,Babar ZU

更新日期：2017-04-01 00:00:00

abstract：:Influenza, the seventh leading cause of death in the USA, accounts for 35,000 deaths and over 200,000 hospitalizations annually in that country alone. Recent advances in influenza vaccines, diagnosis and treatment have created numerous options for practicing clinicians, as well as economic opportunities for the makers...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rothberg M

更新日期：2005-04-01 00:00:00

abstract：:There have been great technological advances in the use of antiretroviral therapies to slow down disease progression in HIV/AIDS. Combinations of therapeutics and the use of several diagnostic methods have resulted in both declines in mortality and the occurrence of opportunistic infections. The higher costs of these ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bos JM,Berg LT,Postma MJ

更新日期：2001-10-01 00:00:00

abstract：:Skin diseases are among the most common health problems worldwide and are associated with a considerable burden. The burden of skin disease is a multidimensional concept that encompasses psychological, social and financial consequences of the skin disease on the patients, their families and on society. Chronic and inc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Basra MK,Shahrukh M

更新日期：2009-06-01 00:00:00

abstract：OBJECTIVE:To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. RESEARCH DESIGN AND METHODS:Two independent contributors reviewed the statements of the TC, recommendations iss...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kawalec P,Malinowski KP,Trąbka W

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. AIM:To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. METH...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gimeno-Ballester V,Mar J,San Miguel R

更新日期：2016-01-01 00:00:00